A primary care physician may make the diagnosis of hyperthyroidism, but help may be needed from an endocrinologist, a physician who is a specialist in thyroid and other endocrine diseases. The best test to determine overall thyroid function is the thyroid stimulating hormone TSH level.
TSH is produced in the brain and travels to the thyroid gland to stimulate the thyroid to produce and release more thyroid hormone. A high TSH level indicates that the body does not have enough thyroid hormone. A TSH level lower than normal indicates there is usually more than enough thyroid hormone in the body and may indicate hyperthyroidism.
When hyperthyroidism develops, free thyroxine T4 and free triiodothyronine T3 levels rise above normal. Other laboratory studies may help identify the cause of hyperthyroidism. Thyroid-stimulating immunoglobulins TSI can be identified in the blood when Graves' disease is the cause of hyperthyroidism.
Thyroid peroxidase antibodies and other anti-thyroid antibodies are also seen in some disorders leading to hyperthyroidism. Currently, there are several effective treatments available for hyperthyroidism depending on the cause, severity, and several other factors. The most common treatments for hyperthyroidism include antithyroid medications, radioactive iodine, and thyroid surgery. Antithyroid medication most often methimazole decreases thyroid hormone production.
Antithyroid medicine does not cure the disease but works while the patient takes the medication. It is not usually recommended as a long term solution, although in some patients the hyperthyroidism does go into remission and the medication can be discontinued.
If the hyperthyroidism does not go into remission after two years, a more definitive treatment is often recommended thyroidectomy or radioactive iodine.
Radioactive iodine RAI is a common treatment for hyperthyroidism. The thyroid is one of the few organs in the body that avidly takes up iodine.
This allows radioactive iodine to selectively damage the thyroid gland without affecting other parts of the body. Hashimoto thyroiditis is a histologic diagnosis.
In this, there is a damage to either thyroglobulin, a protein of the thyroid gland , or thyroid peroxidase an enzyme involved in the production of thyroid hormone Hypothyroidism. In this type of treatment, radioactive iodine, or radioiodine is consumed by mouth. Because the thyroid gland needs iodine to produce hormones, the radioiodine absorbs into the thyroid cells and the process of radioactivity eliminates the overactive thyroid cells over time.
As a result, the thyroid gland shrinks and this helps in lowering the symptoms This side effect is usually mild and temporary, but this treatment is not recommended in case the patient has ophthalmological problems. Since this therapy causes thyroid activity to shrink, it is important that the body is later supplied with normal amounts of thyroid hormones.
These medications do not stop the production of thyroid hormones, but they do stop the effect of hormones on the body. These blockers also offer relief of irregular anxiety, heat intolerance, sweating, muscle weakness, heartbeats, tremors, irritability, and diarrhea. These medications are not recommended to people with asthma, because the drugs may initiate an asthma attack.
In this all or parts of your thyroid subtotal thyroidectomy or thyroidectomy are removed. Replacement therapy with thyroid hormone. Use of the synthetic thyroid hormone levothyroxine, Levoxyl, Synthroid, others.
Certain supplements and medications may influence your ability to absorb levothyroxine. Take any of the following:. Difference Between Similar Terms and Objects. Name required. Total protein concentrations were determined by Bradford assay The same adenovirus stock was always used in an individual experiment. Control immunizations were performed with adenovirus lacking an insert [control adenovirus Con-Ad ] Viruses were propagated in HEK cells and purified by CsCl density gradient centrifugation, and viral particle concentration was determined by absorbance at nm Blood was drawn 1 wk after two injections, and animals were euthanized 1 month after the third injection to harvest blood and thyroid glands.
Animal studies were approved by the Institutional Animal Care and Use Committee at Cedars-Sinai Medical Center and performed with the highest standards of care in a pathogen-free facility. Tanaka, Osaka University, Osaka, Japan, respectively were injected into nude mice to induce ascites. S1, c and d. These studies were conducted according to the principles and procedures in the Guideline for the Care and Use of Laboratory Animals, Nagasaki University.
Thyroids were fixed in buffered formaldehyde pH 7. Serial thyroid sections were examined without knowing the immunization employed or the origin transgenic or wild type of the tissue. Lymphocytic infiltration was assessed as a percentage of the tissue involved.
TSH levels in some mice were determined with a fee for service by Dr. Davies and Tomer; see above. Test sera were diluted , antibody binding was detected with horseradish peroxidase-conjugated mouse anti-IgG Sigma-Aldrich, St. Louis, MO , and the signal was developed with o -phenylenediamine and H 2 O 2. The data are expressed as OD nm. Sera diluted from immunized transgenics and wild-type littermates were tested for mTPO binding in the same way.
Data are expressed as percent positive cells in the gated fraction M2. At the time of previous studies on human TSHR A-subunit transgenic mice bred from five founders 5 , we had no information on the level of A-subunit expression. Retaining three of these transgenic lines, we have now determined by immunohistochemistry that thyrocytes from transgenic lines Although the TSHR holoreceptor is expressed on the basal surface of the thyrocyte, the soluble A-subunit is a secreted protein Thyroids from In contrast, as controls, thyroid concentrations of mTg and total protein were similar in all three transgenic lines and wild-type littermates.
The differences in human A-subunit expression among transgenic lines were unrelated to transgene copy number, with two copies present in Human A-subunit expression in thyroid tissue from transgenic mice.
A, Immunohistochemistry using an anti-5H antibody to detect the 6H tag on the transgenically expressed human A-subunit. Top , Hi-expressor transgenic lines B, Concentrations of human A-subunit, mouse Tg and total protein in thyroid extracts from transgenic lines We have now addressed the question of breaking tolerance in Hi vs. Lo A-subunit expressor transgenics. As expected, wild-type littermates had a robust TBI response 1 wk after the second injection and 1 month after the third injection Fig.
In contrast, Hi-expressor transgenics remained tolerant at both time intervals, even after Treg depletion with anti-CD25 Fig. Although some responses tended to be higher in some CDtreated compared with untreated transgenics, the differences were not significantly different. A, Overview of antibody administration to deplete Treg before immunization with TSHR-Ad, obtaining blood 1 wk after the second immunization and euthanasia 1 month after the third immunization.
Some mice received Con-Ad Con. Sera were tested 1 wk after two adenovirus injections Inj 2x and 1 month after the third immunization 3x. Incidentally, categorization into A-subunit Hi- and Lo-expressor lines permitted reanalysis of previously reported data 5.
Despite detectable TBI activity, no Lo-expressor transgenics developed hyperthyroidism. Surprisingly, 1 wk after the second immunization, serum T 4 levels were subnormal in all Lo-expressors pretreated with anti-CD25 Fig. Some recovery in T 4 levels was evident at euthanasia, 4 wk after the third immunization.
However, four of seven mice pretreated with anti-CD25 had extremely low or undetectable serum T 4 levels Fig. Because of these unusual findings, we measured serum TSH levels in the Lo-expressors and wild-type littermates for which sufficient serum was available at euthanasia.
TSH was markedly elevated in both mice with very low T 4 levels Fig. As shown in Fig. Some mice were injected with Con-Ad Con. Data are shown for individual animals. Serum TSH levels were determined when sufficient serum was available at euthanasia. Arrows indicate elevated TSH values in hypothyroid mice.
Thyroid pathology provided the explanation for the hypothyroidism described above. Consistent with these observations, wild-type littermates and euthyroid Lo-expressor transgenics immunized with TSHR-Ad had normal thyroid histology Fig. Hyperthyroid wild-type mice developed thyroid hyperplasia without infiltrating lymphocytes Fig.
Most striking, however, thyroids of hypothyroid Lo-expressor transgenics Treg depleted with anti-CD25 had massive lymphocyte infiltrates, encompassing much of the thyroid Fig. The extent of thyroid lymphocytic infiltration in both experiments was quantified as the percentage of the thyroid area invaded by lymphocytes. Thyroid lymphocytic infiltration. Data are shown for Lo-expressor transgenics Tgic-Lo and wild-type mice whose T 4 levels are shown in Fig. Thyroid tissue was obtained at euthanasia 4 wk after the third immunization.
The extent percent of the thyroid infiltrated with lymphocytes was estimated without knowledge of the type of mouse or its treatment regimen. Values for the four transgenic mice with hypothyroidism at the time of euthanasia Fig.
Indeed, in association with thyroid lymphocytic infiltration, autoantibodies to murine Tg were present in all anti-CDtreated Lo-expressor transgenics but in no other groups of transgenics or wild-type mice Fig. Intermolecular autoantibody spreading from the TSHR to other thyroid autoantigens. These groups of animals also had the greatest degree of thyroid lymphocytic infiltration Fig. Data are expressed as the percent positive gated cells.
Because of human diversity as well as for obvious ethical limitations, syngeneic animal models of autoimmune diseases are invaluable investigative tools. Unlike their wild-type littermates, A-subunit transgenic mice were resistant to immunization with low-dose A-subunit-Ad, although high-dose A-subunit or holoreceptor adenovirus immunization elicited low-level immune responses 5. In the present report, using immunohistochemistry and analysis of thyroid extracts, we categorized the extent of intrathyroidal A-subunit expression in progeny from the five founders and have studied one Lo-expressor and two Hi-expressor transgenic lines.
The data obtained provide novel insight into tolerance and the role of Treg in the pathogenesis of thyroid autoimmune disease. Immunization of the transgenic lines with TSHR-Ad indicated that Hi-expressor mice had a suppressed or absent immune response compared with Lo-expressors.
These data are consistent with the Hi-expressors having a greater degree of central tolerance, a process in which self-reactive T cells, which bind with high affinity to peptides from self-antigens expressed in the thymus, are deleted. Intrathymic expression of the TSHR has been reported for humans 24 , 25 and rats 26 , but A-subunit mRNA was undetectable in thymic tissue from Hi-expressor mice not shown.
Although some self-antigens, for example Tg 27 , can be studied in thymic tissue predominantly nonexpressing thymocytes , others are studied in thymic medullary epithelial cells We cannot, therefore, exclude a role for peripheral tolerance in the A-subunit transgenics. However, as in mice transgenic for hen egg lysozyme 29 , it is likely that high peripheral expression of the human A-subunit correlates with increased central tolerance and low peripheral expression with decreased tolerance to the TSHR.
It has recently been recognized that thymic expression of several tissue-restricted antigens varies considerably between individuals Therefore, breaking tolerance is inversely related to the extent of A-subunit transgene expressed in the thyroid, and Treg do not appear to play an important role in this process.
A clinical relationship between these two diseases has long been recognized.
0コメント